What if you started a company like Roche (est. in 1896) from the ground up? How would you approach drug development differently given enabling technology available today? That's the question Diego Rey and the other founders of Endpoint Health asked.  Diego Rey is a co-founder and Chief Scientific Office of Endpoint Health, which is flipping the traditional drug development model on its head with a precision-medicine approach. In the past, biopharma companies would start with a molecule and then see where it can be used. Endpoint thinks differently. They are using deep patient insight from the patient’s biology, molecules, digital patient data and the latest in AI technology to create precision-first therapies. Pretty cool and unique approach especially for those who have traditionally been overlooked by generic drugs.  We’re excited to have Diego on to talk more about their approach, the future of precision medicine, and his inaugural work with Y Combinator’s life sciences startups.  About Diego Diego Rey, PhD, is a co-founder, board member, and Chief Scientific Officer of Endpoint Health, a Precision-First™ biopharma company where he employs his background in building multidisciplinary technical teams to create and develop the core technologies that enable Endpoint Health to deliver therapeutics and diagnostics to improve patient care. Diego holds a PhD in Biomedical Engineering from Cornell University with minors in Biophysics and Applied Engineering Physics and a BS in Electrical Engineering from the University of California at Santa Barbara. Prior to Endpoint Health, during his PhD Diego co-founded GeneWEAVE Biosciences that was acquired by Roche where he was Head of Research for the Roche GeneWEAVE Division. After Roche Diego joined Y Combinator as YC’s first life sciences Visiting Partner.  https://www.linkedin.com/in/diegorey/  About Endpoint Endpoint Health is a precision-first™ therapeutics company that building a new kind of biopharma. By rewriting the molecule-first drug development model, Endpoint aims to deliver precision therapies that have the potential to improve outcomes for patients with immune-driven illnesses. Their vision is a world in which all patients get the best treatment possible for their unique biology and disease. https://endpointhealth.com/  https://endpointhealth.com/pipeline/  Qualio Website Previous episodes: https://www.qualio.com/from-lab-to-launch-podcast Apply to be on the show: https://forms.gle/uUH2YtCFxJHrVGeL8 Music by keldez